Drug Profile


Alternative Names: CRYAB; HspB5; Recombinant human alpha B-crystallin - Delta Crystallon; Recombinant human CRYAB - Delta Crystallon

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Delta Crystallon
  • Class Recombinant proteins
  • Mechanism of Action Immunomodulators; Regulatory T-lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Multiple sclerosis
  • Phase I Amyotrophic lateral sclerosis; Progressive supranuclear palsy

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Multiple-sclerosis(In volunteers) in Netherlands (IV, Injection)
  • 25 May 2015 Phase-I clinical trials in Amyotrophic lateral sclerosis in Netherlands (IV) before May 2015
  • 25 May 2015 Phase-I clinical trials in Progressive supranuclear palsy in Netherlands (IV) before May 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top